CAR T cells that target the B-cell maturation antigen produce remissions in patients with relapsed or refractory multiple myeloma. Updated results from a phase I study suggest that 94% of patients treated with the highest doses showed complete or partial remissions and high rates of progression-free survival.
from Cancer via ola Kala on Inoreader http://ift.tt/2nMXMGS
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου